Research and development of daily drug approved by the European EMA Imfinzi, Calquence...

2020.07.28 Research and Development NEWS: Run New Biology Class 1 New Drug Completed Phase 2 Clinical First Patient Administration; AstraZeneca Calquence approved by the European Union for the treatment of CLL; Runnew Bio 1 New Drug Completed Phase 2 Clinical First Patient Administration... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original text) (Drug Development) Moderna New Crown Vaccine Launch Phase 3 Clinical 27, Moderna announced that the company developed the new coronavirus mRNA vaccine (mRNA-1273) phase 3 research has begun to give participants.
Lingke Pharmaceuticals has been authorized to develop new RAS inhibitor Lingco Pharmaceuticals announced on the 27th that it has signed an exclusive licensing agreement with Kobe University and the Japan Institute of Science and Chemistry to develop RAS inhibitors with new drug mechanisms.
Run new biology class 1 new drug completed the second phase of clinical first clinical drug-administered new biology announced that it is in the new drug RX108 treatment of recurrent metastatic head and neck scale cancer phase 2 clinical study recently completed the first patient administration at Shanghai Oriental Hospital.
" Drug Approval" Imfinzi combined chemotherapy first-line treatment of extensive small cell lung cancer was recommended by CHMP on the 27th, AstraZeneca announced that Imfinzi joint lysine and calpsum or cisplatin for the first-line treatment of adult wide-ranging small cell lung cancer was recommended by the European Medicines Agency's Human Use Medicines Committee recommended for sale in the European Union.
the world's first infyxicetic sC dose has been approved for five new indications Celltrion Healthcare, the European Commission has approved Remsima subcutaneous (SC) preparations for all previously approved adult indications, including: aggressive spina bifida, Crohn's disease, ulcerative colitis, psoriasis arthritis, and psoriasis.
Keytruda's sixth listing application in China to be included in the latest publicity of the Priority Review CDE), a new drug listing application for the Mercado PD-1 inhibitor Keytruda is to be included in the priority review, and the reasons for inclusion are subject to conditional approval.
This is Keytruda's sixth listing application in China, according to CDE's website, and indications may be a front-line treatment for advanced hepatocellular carcinoma.
AstraZeneca Has approval for the treatment of CLL AstraZeneca has been approved by the European Union, and the European EmaMen Medical Products Committee has issued an active review recommending the approval of Calquance for the treatment of adult patients with chronic lymphoblastic leukemia (CLL).
new non-opioid painkiller Zynrelef approved by THE EUROPEAN Union CHMP! Recently, Heron announced that the European EMA Human Medical Products Commission has issued an active review recommending that Zynrelef be approved for postoperative pain management.
Concord And Kirin Crysvita Treatment X-Chain Hypophostic Disease Treatment X-Chain Low Phosphoemia Has Been Recommended by The Japanese Pharmaceutical Association and Kirin recently announced that the European EMA Human Pharmaceutical Products Committee has issued a positive review of the proposed expansion of Crysvita's approval to include X-chain hypophoscopy adolescents and adult patients.
the first bird-type mycobacteria-induced non-TUBERculosis tuberita pulmonary drug Arikayce EU will be approved, Insmed announced that the European EMA Human Medicine Products Committee has issued a positive review of the recommendation to approve Arikayce, for the treatment of adult patients with limited selection and cystic fibrosis, treatment of non-TB mycobacteria pulmonary infection caused by osteria.
: Mass screening reveals 21 existing anti-neo-coronavirus drugs! Recently, Nature published the latest research results on the treatment of COVID-19 drugs, identified 100 small molecules that inhibit SARS-CoV-2 replication, including 21 known drugs that show a significant dose response relationship, 13 molecules can be achieved in patients with dose-suppressing viral replication.
.